Renal outcomes of both treatment groups. حسب Marwan El-Deyarbi (21688492)

"…Participants in the multifactorial group achieved a significant mean difference in low-density lipoprotein cholesterol levels (mean difference = −0.14, 95% CI: −0.27–0.001, P < 0.03), and significant adjusted mean difference of eGFR levels difference (3.93 mL/min/1.73 m², 95% CI: 1.27–6.58, P < 0.01) at study completion compared to those in the control group. …"

Forest plots illustrate the mean difference in; (A) hospital stay, (B) ICU stay, (C) intubation time; with subgroup analysis. حسب Mohamed R. Abdelraouf (21501468)

Mean (95% CI) and standard deviation of Co-Contraction index of right and left gluteus medius (MVC%) during 60 minutes standing between two groups. حسب Saeedeh Abbasi (9423189)

Increased NFKB2⁺ cells and decreased ACADM⁺ and ANGPTL4⁺ cells were observed in KIRC tissues. حسب Yu Zhang (12946)

الموضوعات:

Dynamical changes in the buffer population (<i>L</i> = 1023). حسب Ariel Burman (20329776)

The mean number of the emerged <i>D. melanogaster</i> adults. Mean number (±SE) of emerged adults and average percentage (±SE) of the residual fertility at the different treatment... حسب Flavia Cerasti (21655934)

Table 2_Expression and prognostic significance of the m6A RNA methylation regulator HNRNPC in HNSCC.docx حسب Yulin Zhang (510822)

"…Knockdown of HNRNPC in the HNSCC cell lines HSC-3 and CAL-27 resulted in a significant decrease in proliferation, invasion, and malignant transformation abilities. …"

Table 1_Expression and prognostic significance of the m6A RNA methylation regulator HNRNPC in HNSCC.docx حسب Yulin Zhang (510822)

"…Knockdown of HNRNPC in the HNSCC cell lines HSC-3 and CAL-27 resulted in a significant decrease in proliferation, invasion, and malignant transformation abilities. …"

Maximum likelihood estimates of trans-log mean stochastic function. حسب James Anaba Akolgo (14129379)

Summary of post-treatment disease course measures from MDMA-AT publications. حسب Filip Stanicic (17808254)

الموضوعات:

Study selection criteria. حسب Filip Stanicic (17808254)

الموضوعات:

Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications. حسب Filip Stanicic (17808254)

الموضوعات:

Disease course measures after the PTSD treatments. حسب Filip Stanicic (17808254)

الموضوعات:

PICOS criteria for the SLR. حسب Filip Stanicic (17808254)

الموضوعات:

Summary of post-treatment CAPS score changes from MDMA-AT publications. حسب Filip Stanicic (17808254)

الموضوعات:

Summary of post-treatment disease course measures from off-label medications clinical trials. حسب Filip Stanicic (17808254)

الموضوعات:

Summary of post-treatment CAPS score changes from clinical trials with psychotherapies. حسب Filip Stanicic (17808254)

الموضوعات:

Summary of clinical studies of FDA-approved medications for PTSD: Disease course outcomes. حسب Filip Stanicic (17808254)

الموضوعات:

Summary of post-treatment disease course measures from clinical trials with psychotherapies. حسب Filip Stanicic (17808254)

الموضوعات:

PRISMA flow chart. حسب Filip Stanicic (17808254)

الموضوعات: